Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Corcept Therapeutics ( (CORT) ) is now available.
On October 10, 2025, Gillian Cannon, Ph.D., resigned from the Board of Directors of Corcept Therapeutics Incorporated. Her resignation was not due to any disagreements with the company. The company has expressed gratitude for her contributions. In conjunction with her resignation, Dr. Cannon will continue to provide consulting services to the Board until the 2026 stockholders meeting, receiving a monthly fee and maintaining her stock options’ vesting schedule.
The most recent analyst rating on (CORT) stock is a Buy with a $135.00 price target. To see the full list of analyst forecasts on Corcept Therapeutics stock, see the CORT Stock Forecast page.
Spark’s Take on CORT Stock
According to Spark, TipRanks’ AI Analyst, CORT is a Outperform.
Corcept Therapeutics’ overall stock score is driven by strong financial performance and positive earnings call sentiment. While the technical analysis suggests a neutral trend, the high valuation presents a potential risk. The company’s strategic expansions and promising drug pipeline support a positive outlook, despite some operational challenges.
To see Spark’s full report on CORT stock, click here.
More about Corcept Therapeutics
Average Trading Volume: 840,901
Technical Sentiment Signal: Buy
Current Market Cap: $9.29B
For a thorough assessment of CORT stock, go to TipRanks’ Stock Analysis page.